Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients

Nasir Ali Afsar, Mike Ufer, Sierk Haenisch, Cornelia Remmler, Ahmed Mateen, Ahmed Usman, Khwaja Zafar Ahmed, Hakimuddin Razi Ahmad, Ingolf Cascorbi
  • European Journal of Clinical Pharmacology, October 2011, Springer Science + Business Media
  • DOI: 10.1007/s00228-011-1134-0

Genes matter while treating breast cancer.

What is it about?

This publication explores the relationship of a set of genotypes of drug metabolizing enzymes to plasma clearance as well as most common adverse effect of a commonly used cytotoxic and immunosuppressive drug cyclophosphamide. It supports involvement of CYP2C19, ALDH3A1 and GSTA1 in this regard.

Why is it important?

This article explores the genetic basis of variation in breast cancer treatment.

Perspectives

Dr Nasir Ali Afsar
Jinnah Medical & Dental College Karachi; Alfaisal University Riyadh.

It is an important study to understand the behavior of a commonly used drug to treat breast cancer.

Read Publication

http://dx.doi.org/10.1007/s00228-011-1134-0

The following have contributed to this page: Dr Nasir Ali Afsar